A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Goode RW) > A description of th...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		04933naa a2200745 4500
001		oai:gup.ub.gu.se/52305
003		SwePub
008		240528s2004 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
009		oai:lup.lub.lu.se:8444f029-5d09-4561-b1d1-20e3e2c6d0c5
024	7	a https://gup.ub.gu.se/publication/523052 URI
024	7	a https://lup.lub.lu.se/record/8989642 URI
024	7	a https://doi.org/10.1023/B:CARD.0000029032.46744.562 DOI
040		a (SwePub)gud (SwePub)lu
041		a eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Cleland, J. G.4 aut
245	1 0	a A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)
264	1	c 2004
520		a BACKGROUND & AIMS: The COMET trial was a prospective, double-blind, randomised trial comparing carvedilol, a comprehensive adrenergic receptor antagonist, with metoprolol, a beta-1-selective agent in patients with heart failure and left ventricular systolic dysfunction. The trial showed a reduction in mortality with carvedilol that was consistent across subgroups. The purpose of this report is to describe in greater detail the heterogeneity of this population at baseline with particular reference to the impact of symptomatic severity, age and gender on patient characteristics. METHODS: A descriptive report using data entered in the COMET study data-base. RESULTS: The characteristics of the population studied were similar to those reported in previous trials of beta-blockers. Almost all patients were receiving diuretics and ACE inhibitors with few patients taking angiotensin receptor blockers. As expected, older patients had more co-morbidity. Older patients and women reported worse symptoms and poorer well-being despite similar ventricular dimensions and systolic dysfunction. NT-proBNP was higher in patients with more severe symptoms and older patients but not in women, although differences in NT-proBNP may have been confounded by differences in renal function. CONCLUSION: Age and gender, as well as the severity of cardiac dysfunction, appear to have an important effect on the severity of heart failure symptoms and patient 'well-being'. This could have important implications for the relationship between symptoms and prognosis and therefore the way in which patients are selected for clinical trials and the goals of treatment. This will be the subject of further analyses.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Annan klinisk medicin0 (SwePub)302992 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Other Clinical Medicine0 (SwePub)302992 hsv//eng
653		a Adrenergic beta-Antagonists/*therapeutic use
653		a Age Factors
653		a Aged
653		a Body Mass Index
653		a Carbazoles/*therapeutic use
653		a Comorbidity
653		a Double-Blind Method
653		a Female
653		a Heart Failure
653		a Congestive/classification/*drug therapy/etiology
653		a Humans
653		a Male
653		a Metoprolol/*therapeutic use
653		a Middle Aged
653		a Patient Selection
653		a Propanolamines/*therapeutic use
653		a Randomized Controlled Trials
653		a Severity of Illness Index
653		a Sex Factors
653		a heart failure
653		a metoprolol
653		a carvedilol
700	1	a Goode, K.4 aut
700	1	a Erhardt, Leif RWu Lund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups4 aut0 (Swepub:lu)medf-ler
700	1	a Remme, W. J.4 aut
700	1	a Charlesworth, A.4 aut
700	1	a Poole-Wilson, P. A.4 aut
700	1	a Di Lenarda, A.4 aut
700	1	a Hanrath, P.4 aut
700	1	a Komajda, M.4 aut
700	1	a Metra, M.4 aut
700	1	a Swedberg, Karl,d 1944u Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute4 aut0 (Swepub:gu)xsweka
700	1	a Torp-Pedersen, C.4 aut
700	1	a Trop-Pedersen, C4 aut
710	2	a Internmedicin - epidemiologib Forskargrupper vid Lunds universitet4 org
773	0	t Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapyg 18:2, s. 139-52q 18:2<139-52x 0920-3206
856	4	u http://dx.doi.org/10.1023/B:CARD.0000029032.46744.56y FULLTEXT
856	4 8	u https://gup.ub.gu.se/publication/52305
856	4 8	u https://lup.lub.lu.se/record/898964
856	4 8	u https://doi.org/10.1023/B:CARD.0000029032.46744.56

Hitta via bibliotek

Cardiovascular drugs and therapy / sponsored by the International Society of Car... (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Cleland, J. G.; Goode, K.; Erhardt, Leif RW; Remme, W. J.; Charlesworth, A.; Poole-Wilson, P. ...; visa fler...; Di Lenarda, A.; Hanrath, P.; Komajda, M.; Metra, M.; Swedberg, Karl, ...; Torp-Pedersen, C ...; Trop-Pedersen, C; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Kardiologi

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Annan klinisk me ...

Artiklar i publikationen: Cardiovascular d ...

Av lärosätet: Göteborgs universitet; Lunds universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se